What is claimed:

1. A composition comprising:
a) about 1 mg to about 50 mg of a polypeptide comprising a circularly permuted IL-2 fused to the extracellular portion of an IL-2Rα chain;
b) sucrose;
c) mannitol;
c) citrate buffer; and
d) an emulsifier.

2. The composition of claim 1, wherein the polypeptide comprises an amino acid sequence having at least 95% identity to SEQ ID NO: 1.

3. The composition of claim 1, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 1.

4. The composition of any one of claims 1-3, wherein the composition comprises about 1 mg to about 15 mg of the polypeptide.

5. The composition of any one of claims 1-4, wherein the composition comprises about 1 mg of the polypeptide.

6. The composition of any one of claims 1-4, wherein the composition comprises about 5 mg of the polypeptide.

7. The composition of any one of claims 1-4, wherein the composition comprises about 15 mg of the polypeptide.

8. The composition of any one of claims 1-4, wherein the composition comprises about 20 mg of the polypeptide.

9. The composition of any one of claims 1-4, wherein the composition comprises about 30 mg of the polypeptide

10. The composition of any one of the preceding claims, wherein the composition comprises about 60 mg to about 72 mg sucrose.

11. The composition of any one of the preceding claims, wherein the composition comprises about 66 mg sucrose.

12. The composition of any one of the preceding claims, wherein the composition comprises about 60 mg to about 72 mg mannitol.

13. The composition of any one of the preceding claims, wherein the composition comprises about 66 mg mannitol.

14. The composition of any one of the preceding claims, wherein the composition comprises about 4.0 mg to about 6.0 mg citrate anion.

15. The composition of any one of the preceding claims, wherein the composition comprises about 5.0 mg citrate anion.

16. The composition of any one of the preceding claims, wherein the composition comprises citric acid and sodium citrate tribasic dihydrate in a mass ratio of citric acid:sodium citrate tribasic dihydrate of between about 1:10 to about 1:2.

17. The composition of any one of the preceding claims, wherein the composition comprises citric acid and sodium citrate tribasic dihydrate in a mass ratio of citric acid:sodium citrate tribasic dihydrate of about 1:9.

18. The composition of any one of the preceding claims, wherein the composition comprises citric acid and sodium citrate tribasic dihydrate in a mass ratio of citric acid:sodium citrate tribasic dihydrate of about 1:2.

19. The composition of any one of the preceding claims, wherein the emulsifier comprises polysorbate 20.

20. The composition of claim 19, wherein the composition comprises about 0.10 mg to about 0.12 mg polysorbate 20.

21. The composition of claim 19, wherein the composition comprises about 0.11 mg polysorbate 20.

22. The composition of any one of the preceding claims, wherein the composition is a lyophilized cake.

23. The composition of claim 22, wherein dissolution of the lyophilized cake in water results in an aqueous solution with a pH of about 5.5 to about 6.5.

24. The composition of claim 23, wherein dissolution of the lyophilized cake in water results in an aqueous solution with a pH of about 6.1.

25. The composition of any one of claims 22-24, wherein dissolution of the lyophilized cake in water results in an aqueous solution with an isotonic osmolality.

26. The composition of any one of claims 22-25, wherein dissolution of the lyophilized cake in water results in an aqueous solution with an osmolality of about 240 to about 340 mOsm/kg.

27. The composition of any one of claims 22-26, wherein dissolution of the lyophilized cake in water results in an aqueous solution with an osmolality of about 280 to about 320 mOsm/kg.

28. The composition of claim 26, wherein dissolution of the lyophilized cake in water results in an aqueous solution with an osmolality of about 285 mOsm/kg.

29. The composition of claim 26, wherein dissolution of the lyophilized cake in water results in an aqueous solution with an osmolality of about 300 mOsm/kg.

30. The composition of any one of claims 1-29, wherein the composition is an aqueous solution.

31. The composition of claim 30, wherein the composition comprises about 0.5 mg/mL to about 30 mg/mL of the polypeptide.

32. The composition of claim 31, wherein the composition comprises about 1 mg/mL of the polypeptide.

33. The composition of claim 32, wherein the composition is a 1.1 ml aqueous solution comprising about 1.1 mg of the polypeptide.

34. The composition of claim 31, wherein the composition comprises about 5 mg/mL of the polypeptide.

35. The composition of claim 34, wherein the composition is a 1.1 ml aqueous solution comprising about 15 mg of the polypeptide.

36. The composition of claim 31, wherein the composition comprises about 20 mg/mL of the polypeptide.

37. The composition of claim 31, wherein the composition comprises about 30 mg/mL of the polypeptide.

38. The composition of any one of claims 30-37, wherein the composition comprises about 25 mg/mL to about 35 mg/mL sucrose.

39. The composition of claim 38, wherein the composition comprises about 30 mg/mL sucrose.

40. The composition of any one of claims 30-37, wherein the composition comprises about 25 mg/mL to about 35 mg/mL mannitol.

41. The composition of claim 40, wherein the composition comprises about 30 mg/mL mannitol.

42. The composition of any one of claims 30-41, wherein the composition comprises about 10 mM to about 20 mM citrate buffer.

43. The composition of claim 42, wherein the composition comprises about 12 mM citrate buffer.

44. The composition of any one of claims 30-43, wherein the citrate buffer is formed by the combination of 2.03 mg/mL sodium citrate tribasic dihydrate and 0.97 mg/mL citric acid monohydrate in the aqueous solution.

45. The composition of any one of claims 30-43, wherein the citrate buffer is formed by the combination of 2.91 mg/mL sodium citrate tribasic dihydrate and 0.34 mg/mL citric acid monohydrate in the aqueous solution.

46. The composition of any one of claims 30-43, wherein the citrate buffer is formed by the combination of 2.96 mg/mL sodium citrate tribasic dihydrate and 0.30 mg/mL citric acid monohydrate in the aqueous solution.

47. The composition of any one of claims 30-46, wherein the composition comprises about 0.09 mg/mL to about 0.11 mg/mL polysorbate 20.

48. The composition of claim 47, wherein the composition comprises about 0.1 mg/mL polysorbate 20.

49. The composition of any one of claims 30-48, wherein the pH of the composition is about 5.5 to about 6.5.

50. The composition of claim 49, wherein the pH of the composition is about 6.1.

51. The composition of any one of claims 30-50, wherein the osmolality of the composition is about 240 to about 340 mOsm/kg.

52. The composition of any one of claims 30-50, wherein the osmolality of the composition is about 280 to about 320 mOsm/kg.

53. The composition of claim 51, wherein the osmolality of the composition is about 285 mOsm/kg.

54. The composition of claim 51, wherein the osmolality of the composition is about 300 mOsm/kg.

55. The composition of any one of claims 30-54, wherein the aqueous solution comprises about 0.03 mg/mL of the polypeptide to about 0.2 mg/mL of the polypeptide.

56. A lyophilized composition made by lyophilizing the composition of any one of claims 30-55.

57. The composition of any one of the preceding claims, wherein the composition is a single unit dose of the polypeptide.

58. An article of manufacture comprising the composition of any one of the preceding claims.

59. The article of claim 58, which is a glass vial.

60. A method of making a lyophilized composition, the method comprising lyophilizing the aqueous solution of any one of claims 30-55.

61. A method of making an aqueous composition, the method comprising dissolving the composition of claim 22 or 56 in an aqueous solvent.

62. The method of claim 61, wherein the pH of the aqueous composition is adjusted to about 6.1.

63. The method claim 61 or 62, wherein the pH of the aqueous composition is adjusted to about 6.1 with a base.

64. The method of claim 63, wherein the base is sodium hydroxide.

65. The method of any one of claims 61-64, wherein the aqueous composition is further diluted with an aqueous solution comprising about 1% (w/w) of a surfactant.

66. The method of claim 65, wherein the surfactant is polysorbate 20.

67. The method of claim 65, wherein the aqueous solution further comprises about 0.1% (w/w) citric acid monohydrate, 0.2% (w/w) sodium citrate tribasic dihydrate, and 98.7% (w/w) water for injection.

68. A method of activating natural killer cells (NK) cells in a subject, the method comprising administering to the subject an effective amount of the composition of any one of claims 30-55.

69. A method of treating cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of the composition of any one of claims 30-55.

70. The method claim 69, wherein the cancer is renal cell carcinoma, melanoma, ovarian cancer, or lung cancer.

71. The method claim 69 or 70, wherein the cancer comprises a refractory solid tumor.

72. The method of any one of claims 69-71, wherein the composition is administered subcutaneously.

73. The method of any one of claims 69-72, wherein the composition is administered subcutaneously at a dose of about 1 mg to about 15 mg.

74. The method of any one of claims 69-73, wherein the composition is administered subcutaneously at a dose of about 1 mg to about 15 mg once a week (Q1W), once every two weeks (Q2W), or once every three weeks (Q3W).

75. The method of any one of claims 69-73, wherein the melanoma is one or both of mucosal melanoma or advanced cutaneous melanoma.